全球肝病抗病毒药物市场 – 行业趋势及 2029 年预测

市场分析和规模

近年来，预计肝病抗病毒药物市场将在预测期内快速增长。根据 2019 年的研究“世界肝病负担”，肝病每年在全球造成约 200 万人死亡，其中 100 万人死于肝硬化并发症，100 万人死于病毒性肝炎和肝细胞癌。肝硬化是全球第 11 大死亡原因，而肝癌是第 16 大死亡原因。此外，由于非酒精性脂肪肝 (NAFLD) 发病率增加，预计美国慢性肝病死亡率将上升。肝病发病率的增加有助于市场扩张。

Data Bridge Market Research 分析称，2021 年肝抗病毒药物市场价值为 161.1 亿美元，预计到 2029 年将达到 230.5 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 4.58%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

抗病毒药物是一种用于治疗病毒性疾病（如HIV、疱疹、肝炎和流感）的药物。疫苗是这些药物最常见的给药形式。此外，这些药物中的大多数用于治疗特定的病毒感染，但少数药物（广谱抗病毒治疗）对不同形式的病毒有效。用于治疗肝脏病毒感染（如肝炎）的抗病毒药物被称为肝脏抗病毒药物。

报告范围和市场细分

Hepatic Antiviral Drugs Market Dynamics

Drivers

• Increasing prevalence of hepatic disease

The rising prevalence of hepatic disease is a primary driver of the hepatic antiviral drugs market's growth. Changing dietary pattern and sedentary lifestyle are the factors that will enhance the prevalence of urticaria and influencing the market dynamics during the forecast period.  

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hepatic antiviral drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hepatic antiviral drugs market. Additionally, high disposable income and increasing awareness about the treatment will result in the expansion of hepatic antiviral drugs market. Along with this, rising geriatric population and rising incidences of auto-immune disorders will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hepatic antiviral drugs market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the hepatic antiviral drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of hepatic antiviral drugs will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hepatic antiviral drugs market. Additionally, strict regulations and the dearth of awareness about treatment for this illness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hepatic antiviral drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatic antiviral drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hepatic antiviral drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hepatic Antiviral Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency.

COVID-19 has been linked to liver illness in an increasing number of patients. Multiple mechanisms can contribute to COVID19 liver injury, including virus-induced systemic inflammation, hypoxia, hepatic congestion, and drug-induced liver disease. COVID19 has been linked to hepatic decompensation and liver-related death in cirrhotic patients. COVID19's influence on healthcare resources has had a negative impact on chronic liver disease patient treatment and results. As a result, the treatment, diagnosis, and follow-up of individuals with liver disease has decreased, resulting in negative effects for the healthcare industry as a whole. Hence, COVID-19 pandemic had a severe impact on the growth of hepatic antiviral drugs market.

Recent Development

• In December 2021, Pfizer had received the emergency use authorization from U.S. Food and (FDA) for Novel COVID-19 oral antiviral drug named PAXLOVID. PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is approved for emergency use in high-risk adults and children 12 years and older who weigh at least 40 kg.
• In December 2021, Cipla Limited had received the Emergency Use Authorization (EUA) permission by Drug Controller General of India (DCGI) for the launch of oral anti-viral COVID drug named Molnupiravir. Molnupiravir is the first oral antiviral to be authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 infection in people who are at high risk of developing severe disease.

Global Hepatic Antiviral Drugs Market Scope

The hepatic antiviral drugs market is segmented on the basis of application, drugs, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Hepatitis A
• Hepatitis B
• Hepatitis C
• Others

On the basis of application, the global hepatic drugs market is segmented into hepatitis A, hepatitis B, hepatitis C and others.

Drugs

• Entecavir
• Tenofovir
• Lamivudine
• Adefovir
• Telbivudine
• Others

On the basis of drugs, the global hepatic antiviral drugs market is segmented into entecavir, tenofovir, lamivudine, adefovir, telbivudine and others.

Dosage

• Powder
• Tablet
• Solution
• Liquid
• Others

On the basis of dosage, the hepatic antiviral drugs market is segmented into powder, tablet, solution, liquid, and others.  

Route of Administration

• Oral
• Parenteral
• Others

The route of administration segment for the hepatic antiviral drugs market is segmented into oral, parenteral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the hepatic antiviral drugs market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the hepatic antiviral drugs market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Hepatic Antiviral Drugs Market Regional Analysis/Insights

The Hepatic antiviral drugs market is analysed and market size insights and trends are provided by country, application, drugs, dosage, route of administration, end-users and distribution channel as referenced above.

肝抗病毒药物市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于自身免疫性疾病在北美和欧洲地区日益流行，因此它们在抗肝病毒药物市场占据主导地位。此外，主要参与者对新技术的关注度不断提高，这将进一步推动该地区市场的增长率。

由于人口数量和肝病患病率上升，预计预测期内亚太地区将出现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

肝病抗病毒药物竞争格局及市场份额分析

肝抗病毒药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对肝抗病毒药物市场的关注有关。

肝抗病毒药物市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（耶路撒冷）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 礼来公司 (美国)
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 阿斯利康（英国）
• AbbVie Inc.（美国）
• 阿拉宾多制药公司（海得拉巴）
• 鲁宾（孟买）
• 太阳制药工业有限公司（孟买）
• Apotex Inc.（加拿大）
• Amneal Pharmaceuticals LLC.（美国）
• 百时美施贵宝公司 (美国)
• Zydus Cadila（艾哈迈达巴德）
• 吉利德科学公司（美国）
• 强生私人有限公司（美国）
• Cipla Inc.（美国）  

SKU-53133